Keywords: Medivir, Johnson & Johnson, Janssenm Dengue virus, R&D
Medivir enters dengue virus R&D collaboration with Johnson & Johnson unit
Article | 15 February 2011
Swedish infectious disease drug developer Medivir AB (OMX: MVIR) has signed a collaboration agreement with Janssen Pharmaceutica NV, a unit ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
